Previous Close | 3.9700 |
Open | 3.9800 |
Bid | 3.8600 x 800 |
Ask | 3.9800 x 900 |
Day's Range | 3.9376 - 4.3300 |
52 Week Range | 2.2500 - 7.9900 |
Volume | |
Avg. Volume | 236,490 |
Market Cap | 92.153M |
Beta (5Y Monthly) | 0.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.4400 |
Earnings Date | Mar 25, 2024 - Mar 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for DCTH
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO).
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors comprised of existing investors, Delcath Executives and members of its Board of Directors, for a private placement transaction (the "Private Placement").
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in February 2024.